Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research
@icrlordlab.bsky.social
Two heads are better than one ! Joint lab heads. Director & Dept Director Breast Cancer Now Research Centre at @icrlondon.bsky.social. Precision Oncology, HRD, PARPi, synthetic lethality, breast & other cancers. Trying to do some damage.
1/ Very excited to share the first publication from my lab! In this work, we developed an efficient strategy to precisely mutate mammalian histone genes in their native genomic context using CRISPR prime editing: www.nature.com/articles/s41...
Identifying critical lysines in mammalian histone H3 with high-throughput CRISPR prime editing - Nature Genetics
This study uses a precise and efficient clustered regularly interspaced short palindromic repeats (CRISPR) prime editing system to substitute lysine residues in histone H3, individually or in combinat...
nature.com
@arsenalfc.bsky.social a valiant loss. We took the fight to a skilful team and if were to loose, it wasn’t because we were poorer. Still crying at what might have been. We fight again.
Bea has been a stalwart of research at the Breast Cancer Now Centre since its inception. Seeing her contribution recognised like this is great.
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research@icrlordlab.bsky.social · 3mo agowww.linkedin.com/pulse/beatri...
Beatrice Howard: Celebrating a Remarkable Scientific Career
As Beatrice Howard prepares to retire at the end of May 2026, after more than three decades at The Institute of Cancer Research, London, we reflect on a career defined by scientific excellence, collab...
linkedin.com
If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.
Two decades of PARP inhibitor synthetic lethality in cancer - Nature
The past two decades of PARP inhibitor synthetic lethality in cancer is explored.
nature.com
We show that normally germline‑restricted HORMAD1 induces aneuploidy in TNBC by disrupting Aurora B/INCENP and weakening spindle assembly checkpoint. This creates sensitivity to MPS1, Aurora B, and BUB1 inhibitors. Work @icr.ac.uk funded by @breastcancernow.bsky.social and published rdcu.be/e7Som
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors
Nature Communications - HORMAD1 expression is typically restricted to germline cells where it has an important role in meiotic recombination but has been shown to be upregulated in triple negative...
rdcu.be
Our new study is out in Nature Communications. Using TNBC organoid mouse models, we show that necroptosis in both tumour and stromal compartments cooperatively drives effective responses to immunogenic cell death–based immunotherapy. 🔗 www.nature.com/articles/s41...
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy - Nature Communications
Most advanced triple-negative breast cancers remain resistant to immunotherapy. Here, the authors discover that RIPK1-driven necroptosis in both tumor and stromal compartments is essential for effecti...
nature.com
Has anybody a serious argument against funding this.
Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social
Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org
We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...
PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) in Chelsea | The Institute of Cancer Research
View details and apply for this PDTF - Homologous Recombination Defective Cancers ( Profs Chris Lord and Andrew Tutt) vacancy in Chelsea . Salary: Dependent on relevant Postdoctoral exp...
jobs.icr.ac.uk
RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.
Thrilled to share our latest work, just published in @nature.com ⬇ www.nature.com/articles/s41... We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors. 🧵 (1/8)
NASP modulates histone turnover to drive PARP inhibitor resistance - Nature
PARP inhibitor treatment triggers histone release from the chromatin in cancer cells; consequently, targeting the histone chaperone NASP renders cells vulnerable to PARP inhibition.
nature.com
our bit funded by @breastcancernow.bsky.social @cancerresearchuk.org and carried out @icr.ac.uk
Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research@icrlordlab.bsky.social · last yr.With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
Nature Communications - The RNA editing enzyme ADAR1 blocks interferon responses triggered by cytosolic RNA sensors, and has been proposed as a potential target in immuno-oncology. Here, the...
rdcu.be
Academic writing is a craft. ✍️ You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well. Your writing is the first thing people see before they meet you. Make it count.
Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️ 🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk #bcsm #ai #CancerResearch
The Lister Institute of Preventive Medicine@thelisterinstitute.bsky.social · last yr.We are very proud to introduce our brand new 2025 #ListerFellows! This year there are eight Prize recipients. lister-institute.org.uk/a-warm-welco...
🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR
2nd European Cancer Dependency Map Symposium - Human Technopole
The 2nd European Cancer Dependency Map Symposium is a scientific event open to the national and international scientific community working in computational genomics, pharmacogenomics, and therapeutic ...
humantechnopole.it
Human Technopole@humantechnopole.bsky.social · last yr.🔬 Join us in Milan for the 2nd European Cancer Dependency Map Symposium #ECDM25! A key event for scientists in functional genomics & target discovery. Talks, panels, AI & poster sessions await. Register now 👉 humantechnopole.it/en/trainings...
Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open! humantechnopole.it/en/trainings... youtu.be/x2erCuovGvc #EuroDepMap
1st European Cancer Dependency Map Symposium
YouTube video by Human Technopole
youtu.be
www.fiercebiotech.com/biotech/uk-u...
UK unveils £1B plan to become leading cancer research hub just outside the Golden Triangle
The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 billion ($1.3 billion) cancer research and manufacturing hub on the outskirts | ...
fiercebiotech.com
We're looking for a Scientific Operations Project Manager to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...
Scientific Operations Project Manager in Chelsea | The Institute of Cancer Research
View details and apply for this Scientific Operations Project Manager vacancy in Chelsea . Salary : Commencement on the salary range is subject to comparable skills and experience. Future p...
jobs.icr.ac.uk
pubmed.ncbi.nlm.nih.gov/28535155/
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells - PubMed
Although loss of p53 might allow tumour cells to tolerate elevated APOBEC3B expression, continued expression of this enzyme might impart a number of therapeutic vulnerabilities upon tumour cells.
pubmed.ncbi.nlm.nih.gov
Rémi Buisson@buissonlab.bsky.social · last yr.Many thanks to @pedroorteg.bsky.social for leading this work, and to @johnmaciejowski.bsky.social and the Abby Green Lab for their contributions to the story.
The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer www.nature.com/articles/s41... ✅Sac-TMT significantly improved progression-free survival PFS
